Pharsight

Isturisa is owned by Recordati Rare.

Isturisa contains Osilodrostat Phosphate.

Isturisa has a total of 6 drug patents out of which 0 drug patents have expired.

Isturisa was authorised for market use on 06 March, 2020.

Isturisa is available in tablet;oral dosage forms.

Isturisa can be used as cushing's disease.

Drug patent challenges can be filed against Isturisa from 2024-03-06.

The generics of Isturisa are possible to be released after 12 October, 2035.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8835646	RECORDATI RARE	Organic compounds	Aug, 2026 (3 years from now)
US8314097	RECORDATI RARE	Organic compounds	Mar, 2029 (5 years from now)
US9434754	RECORDATI RARE	Use of an adrenal hormone-modifying agent	Jan, 2031 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862	RECORDATI RARE	Use of an adrenal hormone-modifying agent	Jan, 2031 (7 years from now)
US10143680	RECORDATI RARE	Pharmaceutical dosage forms	Jul, 2035 (12 years from now)
US10709691	RECORDATI RARE	Pharmaceutical dosage forms	Oct, 2035 (12 years from now)